GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Earnings per Share (Diluted)

BRAIN Biotech AG (XTER:BNN) Earnings per Share (Diluted) : €-0.37 (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Earnings per Share (Diluted)?

BRAIN Biotech AG's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.09. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.37.

BRAIN Biotech AG's EPS (Basic) for the three months ended in Mar. 2024 was €-0.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.37.

BRAIN Biotech AG's EPS without NRI for the three months ended in Mar. 2024 was €-0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.37.

During the past 3 years, the average EPS without NRIGrowth Rate was 10.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.70% per year.

During the past 9 years, BRAIN Biotech AG's highest 3-Year average EPS without NRI Growth Rate was 15.20% per year. The lowest was -6.00% per year. And the median was 7.50% per year.


BRAIN Biotech AG Earnings per Share (Diluted) Historical Data

The historical data trend for BRAIN Biotech AG's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Earnings per Share (Diluted) Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only -0.61 -0.52 -0.25 -0.30 -0.38

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.08 -0.08 -0.12 -0.09

Competitive Comparison of BRAIN Biotech AG's Earnings per Share (Diluted)

For the Specialty Chemicals subindustry, BRAIN Biotech AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's PE Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's PE Ratio falls into.



BRAIN Biotech AG Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

BRAIN Biotech AG's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2023 is calculated as

Diluted Earnings Per Share (A: Sep. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.279-0)/21.847
=-0.38

BRAIN Biotech AG's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.918-0)/21.847
=-0.09

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


BRAIN Biotech AG  (XTER:BNN) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


BRAIN Biotech AG Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines